Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC
Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With Biliary Tract Cancer: A Single-arm, Phase II Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Lu Wang, M.D
- Phone Number: +86-18121299357
- Email: w.lr@hotmail.com
Study Contact Backup
- Name: Ti Zhang, M.D
Study Locations
-
-
-
Shanghai, China
- Fudan University Shanghai Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Ages 18 and above
- Pathological reported showed Biliary tract cancer (include intrahepatic cholangiocarcinoma (IHCC), extrahepatic/hilar cholangiocarcinoma, muscle infiltrated gallbladder carcinoma or distal cholangiocarcinoma),patients received R0 resection(including liver resection, pancreatectomy, or both).
- ECOG PS 0-1
- Patients can tolerate the combination therapy and survive longer than 6 months.
- Organ function(Exclude use blood components and cell growth factors for 14 days): Neutrophils (ANC) ≥1,500/mm3, Platelet count (PLT)≥100,000/mm3, Hemoglobin (Hb) ≥9g/dL; Serum creatinine(SCR) ≤1.5*upper limit of normal(ULN),or creatinine clearance rate≥50 ml/min(Cockcroft-Gault Formula),Total bilirubin(TBIL)≤ 2*ULN,Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 3*ULN, urine protein≤2+(if urine protein≥2+, 24-hour urinary protein quantity must ≤1g), Adequate surgical biliary drainage and no infection signal.
- The coagulation function was normal (without active bleeding and thrombotic disease): International normalized ratio(INR)≤1.5*ULN, activated partial thromboplastin time(APTT)≤1.5×ULN, prothrombin time(PT)≤1.5*ULN.
- Women without surgical sterilization or childbearing age who are required to use a medically approved contraceptive method (such as an intrauterine device, birth control pill or condom) during the study period and for 3 months after the study period; Women are of reproductive age and not undergoing surgical sterilization whose the serum or urine HCG test must be negative within 7 days prior to study enrollment and must be non lactation period. Male patients without surgical sterilization or reproductive age are required to consent with their spouse to use a medically approved contraceptive method during the study treatment period and for 3 months after the study treatment period.
- The patients are voluntarily enrolled in the study, with good compliance and coordinate the follow-up for safety and survival
Exclusion Criteria:
- Patients with pancreatic/ampullary carcinoma
- Patients with mucous gallbladder carcinoma
- Patients who had received radiotherapy or chemotherapy previously
- Incomplete surgery recovery or biliary obstruction exist
- Patients with radiographs confirmed distant metastases
- Patients with prior or concurrent malignancy(excluded Cured basal cell carcinoma of the skin and Carcinoma in situ elsewhere)
- Patients are allergy to macromolecular protein preparation(including anti-PD-1 antibody, uracil, cytosine pharmaceutical ingredients)
- There are significant factors affecting oral drug absorption, such as inability to swallow, chronic diarrhea, and intestinal obstruction
- Patients had any active autoimmune disease or had experience of autoimmune disease.
- Patients are receiving immunosuppressant and continue using within 2 weeks before enrollment
- Patients with ascites or pleural effusion requiring therapeutic puncture or drainage
- Patients with disease of the heart that are not well controlled
- Abnormal coagulation(have tendency to bleed or receiving thrombolytic or anticoagulant therapy)
- Patients had active infection or unexplained fever during screening and before first dose
- Patients had abdominal fistula, gastrointestinal perforation, or abdominal abscess less than 4 weeks before first dose.
- Patients past or present with pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-related pneumonia, severely impaired lung function, etc
- Patients have congenital or acquired immune deficiency; Hepatitis B patients: HBV DNA≥10^3/ml, Hepatitis C patients: HCV RNA≥10^3/ml, Chronic hepatitis B virus carriers: HBV DNA<2000 IU/ml(<10^4 copies/ml), patients must receive antiviral therapy during the trial
- Patients are participating in other relevant clinical studies or it has been less than 1 month since the end of the previous clinical study; Patients maybe receive other systemic antitumor therapy during the study period;
- Patients received live vaccination less than 4 weeks before administration or possibly receive during the study period.
- Patients had history of psychotropic substance abuse, alcohol abuse, or drug abuse.
- Patients cannot or does not agree to pay the cost of examination and treatment expense
- The researchers concluded the patients should be excluded from this study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: combined treatment group
Capecitabine combined with lenvatinib and tislelizumab: Lenvatinib,8mg po.
qd.Tislelizumab,200mg iv.
q3w.
Capecitabine 1250mg/m^2 bid.d1-d14
q3w
|
Capecitabine combined with lenvatinib and tislelizumab
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
1 year DFS rate
Time Frame: 12 month
|
one year disease free survival rate
|
12 month
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
2 years DFS rate
Time Frame: 24 month
|
two years disease free survival rate
|
24 month
|
|
1 year OS rate
Time Frame: 12 month
|
one year overall survival rate
|
12 month
|
|
3 years OS rate
Time Frame: 36 month
|
three years overall survival rate
|
36 month
|
|
AE
Time Frame: 30 days from the beginning of treatment to the last treatment
|
adverse event
|
30 days from the beginning of treatment to the last treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Site
- Neoplasms
- Digestive System Neoplasms
- Digestive System Diseases
- Biliary Tract Diseases
- Biliary Tract Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Protein Kinase Inhibitors
- lenvatinib
- tislelizumab
Other Study ID Numbers
Other Study ID Numbers
- BTC-CaLenT
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.